Literature DB >> 1328829

SA-11 rotavirus binding to human serum lipoproteins.

F Superti1, L Seganti, M Marchetti, M L Marziano, N Orsi.   

Abstract

An investigation of SA-11 rotavirus binding to human serum lipoproteins was carried out. Various subclasses of lipoproteins, purified by ultracentrifugal flotation, and apoproteins were tested for their activity in inhibiting viral infectivity and hemagglutination. All tested lipoprotein subclasses (very low, low and high density, lipoproteins; VLDL, LDL, HDL, HDL1) were shown to interact with SA-11 rotavirus: VLDL and LDL were the most active in preventing rotavirus replication, whereas HDL and HDL1 inhibited viral hemagglutination to a greater extent. Moreover, A1 and A2 apoproteins were effective towards both viral infectivity and hemagglutination. Results obtained are in agreement with a preferential interaction of VP7 or VP4 proteolytic products with low density lipoproteins and of VP8* with high density lipoproteins. Binding of SA-11 to lipoproteins or apoproteins was also quantified by an enzyme-linked immunosorbent assay procedure and lipoproteins-virus interaction was visualized by electron microscopy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328829     DOI: 10.1007/bf00189426

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  24 in total

Review 1.  The recognition event between virus and host cell receptor: a target for antiviral agents.

Authors:  T L Lentz
Journal:  J Gen Virol       Date:  1990-04       Impact factor: 3.891

2.  Separation of plasma lipoproteins by density-gradient ultracentrifugation.

Authors:  T G Redgrave; D C Roberts; C E West
Journal:  Anal Biochem       Date:  1975-05-12       Impact factor: 3.365

Review 3.  Rotavirus gastroenteritis.

Authors:  A V Bartlett; A J Bednarz-Prashad; H L DuPont; L K Pickering
Journal:  Annu Rev Med       Date:  1987       Impact factor: 13.739

4.  Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4.

Authors:  S M Matsui; P A Offit; P T Vo; E R Mackow; D A Benfield; R D Shaw; L Padilla-Noriega; H B Greenberg
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

5.  SA11 rotavirus is specifically inhibited by an acetylated sialic acid.

Authors:  R E Willoughby; R H Yolken
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

6.  Rotaviruses specifically bind to the neutral glycosphingolipid asialo-GM1.

Authors:  R E Willoughby; R H Yolken; R L Schnaar
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

7.  Pathogenesis of rotavirus infection in mice.

Authors:  L M Little; J A Shadduck
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

8.  Attachment of SA-11 rotavirus to erythrocyte receptors.

Authors:  J W Bastardo; I H Holmes
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

9.  Gangliosides as binding sites in SA-11 rotavirus infection of LLC-MK2 cells.

Authors:  F Superti; G Donelli
Journal:  J Gen Virol       Date:  1991-10       Impact factor: 3.891

10.  Characterization of binding of simian rotavirus SA-11 to cultured epithelial cells.

Authors:  D J Keljo; A K Smith
Journal:  J Pediatr Gastroenterol Nutr       Date:  1988 Mar-Apr       Impact factor: 2.839

View more
  2 in total

1.  Identification of a type 1 peroxisomal targeting signal in a viral protein and demonstration of its targeting to the organelle.

Authors:  K V K Mohan; I Som; C D Atreya
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Interactions between Hepatitis C Virus and the Human Apolipoprotein H Acute Phase Protein: A Tool for a Sensitive Detection of the Virus.

Authors:  Ilias Stefas; Sylvia Tigrett; Grégor Dubois; Marco Kaiser; Estelle Lucarz; Delphine Gobby; Dorothy Bray; Heinz Ellerbrok; Jean Pierre Zarski; Francisco Veas
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.